In myeloid malignancies utilizing CRISPR-Cas9 to generate isogenic human leukemia cell lines of the most common TP53 missense mutations, Boettcher and colleagues identified that TP53 missense mutations result in a dominant-negative effect, ultimately leading to a selection advantage when exposed to DNA damage [12]. Here, TP53 is linked to leukemia.